Jacobio Pharmaceuticals' IND for BET Inhibitor JAB-8263 in Autoimmune Diseases Accepted for Phase I/II Clinical Trial Review

Reuters

2025/07/03

<a href="https://laohu8.com/S/01167">Jacobio</a> Pharmaceuticals' IND for BET Inhibitor JAB-8263 in Autoimmune Diseases Accepted for Phase I/II Clinical Trial Review

Jacobio Pharmaceuticals Group Co. Ltd. has announced that its Investigational New Drug $(IND.AU)$ application for the Phase I/II clinical trial of its BET inhibitor, JAB-8263, for the treatment of autoimmune diseases, has been accepted by the Center for Drug Evaluation $(CDE)$ in China. This marks a significant step in expanding the therapeutic applications of JAB-8263 beyond oncology, where it has previously demonstrated good tolerability in clinical trials for solid tumors and hematological malignancies. The review of the IND application is expected to be completed within 30 working days, bringing hope for new oral treatment options in a field predominantly dominated by intravenous monoclonal antibodies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN23310) on July 03, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548841862"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548841862\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548841862?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-03 08:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548841862","market":"us","top_or_hot":-1,"title":"Jacobio Pharmaceuticals' IND for BET Inhibitor JAB-8263 in Autoimmune Diseases Accepted for Phase I/II Clinical Trial Review","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01167\">Jacobio</a> Pharmaceuticals' IND for BET Inhibitor JAB-8263 in Autoimmune Diseases Accepted for Phase I/II Clinical Trial Review\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced that its Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application for the Phase I/II clinical trial of its BET inhibitor, JAB-8263, for the treatment of autoimmune diseases, has been accepted by the Center for Drug Evaluation <a href=\"https://laohu8.com/S/CDE\">$(CDE)$</a> in China. This marks a significant step in expanding the therapeutic applications of JAB-8263 beyond oncology, where it has previously demonstrated good tolerability in clinical trials for solid tumors and hematological malignancies. The review of the IND application is expected to be completed within 30 working days, bringing hope for new oral treatment options in a field predominantly dominated by intravenous monoclonal antibodies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN23310) on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio Pharmaceuticals' IND for BET Inhibitor JAB-8263 in Autoimmune Diseases Accepted for Phase I/II Clinical Trial Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio Pharmaceuticals' IND for BET Inhibitor JAB-8263 in Autoimmune Diseases Accepted for Phase I/II Clinical Trial Review\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-03 08:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01167\">Jacobio</a> Pharmaceuticals' IND for BET Inhibitor JAB-8263 in Autoimmune Diseases Accepted for Phase I/II Clinical Trial Review\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced that its Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application for the Phase I/II clinical trial of its BET inhibitor, JAB-8263, for the treatment of autoimmune diseases, has been accepted by the Center for Drug Evaluation <a href=\"https://laohu8.com/S/CDE\">$(CDE)$</a> in China. This marks a significant step in expanding the therapeutic applications of JAB-8263 beyond oncology, where it has previously demonstrated good tolerability in clinical trials for solid tumors and hematological malignancies. The review of the IND application is expected to be completed within 30 working days, bringing hope for new oral treatment options in a field predominantly dominated by intravenous monoclonal antibodies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN23310) on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL7W79pk:1","article_id":"2548841862","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548841862","pubTimestamp":1751502616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jacobio Pharmaceuticals Group Co. Ltd. has announced that its Investigational New Drug  application for the Phase I/II clinical trial of its BET inhibitor, JAB-8263, for the treatment of autoimmune diseases, has been accepted by the Center for Drug Evaluation  in China. This marks a significant step in expanding the therapeutic applications of JAB-8263 beyond oncology, where it has previously demonstrated good tolerability in clinical trials for solid tumors and hematological malignancies. The review of the IND application is expected to be completed within 30 working days, bringing hope for new oral treatment options in a field predominantly dominated by intravenous monoclonal antibodies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","01167":"加科思-B"},"translate_title":"Jacobio Pharmaceuticals治疗自身免疫性疾病的BET抑制剂JAB-8263 IND接受I/II期临床试验审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":0.9},"content_text":"Jacobio Pharmaceuticals' IND for BET Inhibitor JAB-8263 in Autoimmune Diseases Accepted for Phase I/II Clinical Trial Review\n    \n\n        Jacobio Pharmaceuticals Group Co. Ltd. has announced that its Investigational New Drug $(IND.AU)$ application for the Phase I/II clinical trial of its BET inhibitor, JAB-8263, for the treatment of autoimmune diseases, has been accepted by the Center for Drug Evaluation $(CDE)$ in China. This marks a significant step in expanding the therapeutic applications of JAB-8263 beyond oncology, where it has previously demonstrated good tolerability in clinical trials for solid tumors and hematological malignancies. The review of the IND application is expected to be completed within 30 working days, bringing hope for new oral treatment options in a field predominantly dominated by intravenous monoclonal antibodies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN23310) on July 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}